Prostate Cancer
James L. Mohler, Robert R. Bahnson, Barry Boston, J. Erik Busby, Anthony V. D’Amico, James A. Eastham, Charles A. Enke(UCSF Helen Diller Family Comprehensive Cancer Center), Daniel George, Eric M. Horwitz(Roswell Park Comprehensive Cancer Center), Robert P. Huben, Philip W. Kantoff, Mark H. Kawachi, Michael Kuettel, Paul H. Lange, Gary R. MacVicar, Elizabeth R. Plimack, Julio M. Pow‐Sang, Mack Roach, Eric Rohren(Roswell Park Comprehensive Cancer Center), Bruce J. Roth, Dennis C. Shrieve(UCSF Helen Diller Family Comprehensive Cancer Center), Matthew R. Smith, Sandy Srinivas, Przemyslaw Twardowski, Patrick C. Walsh
Cited by 902Open Access
Abstract
In the late 1980s and early 1990s, the number of newly diagnosed prostate cancers in the United States increased dramatically, surpassing lung cancer as the most common cancer in men. For example, the percentage of patients with low-risk disease has increased (45.3% in 1999-2001 vs. 29.8% in 1989-1992; P < .0001). In 2009, an estimated 192,280 new cases were diagnosed and prostate cancer was expected to account for 25% of new cancer cases in men. 1 Fortunately, the age-adjusted death rates from prostate cancer have also declined (-4.1% annually from 1994 to 2001).
Related Papers
Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council trial
Reza Adib, John Anderson, M Handley Ashken et al.|Kent Academic Repository (University of Kent)|1997|552